Paper34066908
Intratumoral (Poly-ICLC) Therapy for Dogs with Advanced Cancers: First Report on Clinical Effectiveness, Quality of Life, and Adverse Events.
Voges ARN and 6 others. Cancers (Basel), 2021. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Intratumoral (Poly-ICLC) Therapy for Dogs with Advanced Cancers: First Report on Clinical Effectiveness, Quality of Life, and Adverse Events. Papers, record 34066908. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34066908
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Intratumoral (Poly-ICLC) Therapy for Dogs with Advanced Cancers: First Report on Clinical Effectiveness, Quality of Life, and Adverse Events.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| PEI 0069/15 | Financiadora de Estudos e Projetos | PubMed |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30962585 | Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. | Nat Med | 2019 | https://conductscience.org/library/papers/30962585 | PubMed |
| 2 | 402107 | Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex. | Antimicrob Agents Chemother | 1977 | https://conductscience.org/library/papers/402107 | PubMed |
| 3 | 22065672 | Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. | J Exp Med | 2011 | https://conductscience.org/library/papers/22065672 | PubMed |
| 4 | 28848723 | A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect. | J Hepatocell Carcinoma | 2017 | https://conductscience.org/library/papers/28848723 | PubMed |
| 5 | 28678778 | An immunogenic personal neoantigen vaccine for patients with melanoma. | Nature | 2017 | https://conductscience.org/library/papers/28678778 | PubMed |
| 6 | 30753611 | Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. | Neuro Oncol | 2019 | https://conductscience.org/library/papers/30753611 | PubMed |
| 7 | 8727138 | Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. | Neurosurgery | 1996 | https://conductscience.org/library/papers/8727138 | PubMed |
| 8 | 18262679 | TLR3: interferon induction by double-stranded RNA including poly(I:C). | Adv Drug Deliv Rev | 2008 | https://conductscience.org/library/papers/18262679 | PubMed |
| 9 | 30568303 | Actively personalized vaccination trial for newly diagnosed glioblastoma. | Nature | 2019 | https://conductscience.org/library/papers/30568303 | PubMed |
| 10 | 26545847 | Cancer immunotherapy in veterinary medicine: Current options and new developments. | Vet J | 2016 | https://conductscience.org/library/papers/26545847 | PubMed |
| 11 | 6163381 | Minimal interferon induction in dogs, using a modified polyriboinosinic-polyribocytidylic acid complex. | Am J Vet Res | 1980 | https://conductscience.org/library/papers/6163381 | PubMed |
| 12 | 30500529 | Putting the Immunologic Brakes on Cancer. | Cell | 2018 | https://conductscience.org/library/papers/30500529 | PubMed |
| 13 | 29224713 | Veterinary Oncology Immunotherapies. | Vet Clin North Am Small Anim Pract | 2018 | https://conductscience.org/library/papers/29224713 | PubMed |
| 14 | 32958686 | Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32958686 | PubMed |
| 15 | 29950349 | Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29950349 | PubMed |
| 16 | 18797818 | A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). | J Neurooncol | 2009 | https://conductscience.org/library/papers/18797818 | PubMed |
| 17 | 33011064 | Poly-ICLC, a multi-functional immune modulator for treating cancer. | Semin Immunol | 2020 | https://conductscience.org/library/papers/33011064 | PubMed |
| 18 | 24309609 | Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. | J Pediatr Hematol Oncol | 2014 | https://conductscience.org/library/papers/24309609 | PubMed |
| 19 | 19615405 | Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity. | Pharmacol Ther | 2009 | https://conductscience.org/library/papers/19615405 | PubMed |
| 20 | 26056372 | Comparative oncology: what dogs and other species can teach us about humans with cancer. | Philos Trans R Soc Lond B Biol Sci | 2015 | https://conductscience.org/library/papers/26056372 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 36831676 | Translational and Comparative Research on Innovative Anti-Cancer Therapies. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36831676 |
Source PubMed
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EIF2AK2 | 5610 | PubTator's text mining | https://conductscience.org/library/genes/5610 | NCBI Gene |
| IFIH1 | 64135 | PubTator's text mining | https://conductscience.org/library/genes/64135 | NCBI Gene |
| IFNA1 | 3439 | PubTator's text mining | https://conductscience.org/library/genes/3439 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| RET | 5979 | PubTator's text mining | https://conductscience.org/library/genes/5979 | NCBI Gene |
| RIGI | 23586 | PubTator's text mining | https://conductscience.org/library/genes/23586 | NCBI Gene |
| TLR3 | 7098 | PubTator's text mining | https://conductscience.org/library/genes/7098 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34066908
GET https://conductscience.org/api/papers/v1/34066908/references?page=2